Shell Asset Management Co. maintained its position in shares of Halyard Health, Inc. (NYSE:HYH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,704 shares of the medical instruments supplier’s stock at the end of the second quarter. Shell Asset Management Co.’s holdings in Halyard Health were worth $1,127,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the stock. Adams Diversified Equity Fund Inc. boosted its position in shares of Halyard Health by 2.7% in the first quarter. Adams Diversified Equity Fund Inc. now owns 26,200 shares of the medical instruments supplier’s stock valued at $998,000 after buying an additional 700 shares in the last quarter. Piermont Capital Management Inc. purchased a new position in shares of Halyard Health during the first quarter valued at approximately $2,463,000. Alambic Investment Management L.P. boosted its position in shares of Halyard Health by 57.3% in the first quarter. Alambic Investment Management L.P. now owns 36,800 shares of the medical instruments supplier’s stock valued at $1,402,000 after buying an additional 13,400 shares in the last quarter. UBS Group AG boosted its position in shares of Halyard Health by 32.3% in the first quarter. UBS Group AG now owns 97,585 shares of the medical instruments supplier’s stock valued at $3,717,000 after buying an additional 23,819 shares in the last quarter. Finally, Capstone Asset Management Co. purchased a new position in shares of Halyard Health during the first quarter valued at approximately $203,000. 90.28% of the stock is owned by institutional investors.

Halyard Health, Inc. (NYSE:HYH) opened at 42.61 on Monday. The firm has a 50-day moving average of $39.44 and a 200-day moving average of $38.58. The stock has a market cap of $1.99 billion, a PE ratio of 40.97 and a beta of 1.78. Halyard Health, Inc. has a 1-year low of $31.59 and a 1-year high of $42.96.

Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.14. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The business had revenue of $399.20 million during the quarter, compared to analyst estimates of $399.16 million. During the same period last year, the firm posted $0.45 EPS. The company’s revenue was down .2% on a year-over-year basis. Analysts expect that Halyard Health, Inc. will post $1.96 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/07/shell-asset-management-co-maintains-stake-in-halyard-health-inc-nysehyh.html.

A number of research firms have commented on HYH. TheStreet raised shares of Halyard Health from a “c” rating to a “b” rating in a research note on Thursday, June 22nd. BidaskClub cut shares of Halyard Health from a “buy” rating to a “hold” rating in a research note on Saturday, July 8th. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research note on Wednesday, July 12th. Deutsche Bank AG boosted their price target on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $42.25.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Want to see what other hedge funds are holding HYH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halyard Health, Inc. (NYSE:HYH).

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.